Linkedin
Sign in
Join
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Create an account
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Type here...
Search
Home
About
Editor’s Corner
Contribute
Contact Us
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner
Instagram
Linkedin
Twitter
Subscribe
Subscribe
Friday, February 20, 2026
24.7
C
Bengaluru
Home
About
Editor’s Corner
Contribute
Contact Us
My account
Get into your account.
Login
Register
type here...
Search
Facebook
Linkedin
Twitter
Youtube
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
Novo Nordisk — Septerna’s $2.2 Billion Deal
0
A New Era for Obesity Pills Novo Nordisk has announced...
Semaglutide – More Than Just a Patent Battle
0
The Delhi High Court has restrained Dr. Reddy’s and...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
0
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
0
In a bold move to strengthen its hepatology pipeline,...
Who Is Monitoring Quality in India’s Small Drug Units?
0
The Telangana Drugs Control Administration’s stop-use notice on a...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Marketing
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Policies/Sales
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Strategy
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Subscribe
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
Bring Your Own Learning
0
Articles by K. Hariram, Vivek Hattangadi, DigiPharmaX, Satya Mahesh, Ajesh Shah and Phanish Chandra
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
National Seminar on UCPMP
0
The seminar will help companies especially Product Management Teams and Sales Teams to understand their changing roles due to UCPMP. It will also bring clarity on strategies and promotional inputs including CME's, sampling, gifts etc.
A Social Experiment
0
Articles by K. Hariram, Vivek Hattangadi, Hanno Wolfram, RB Balakrishna and Rajiv Jayaraman
Torrent Pharma–JB Chemicals Acquisition Report
0
Summary Torrent Pharmaceuticals (TRP) has signed definitive agreements...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Marketing
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Policies/Sales
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Strategy
India’s Pharma Renaissance: Private Equity at the Helm
0
Indian pharmaceuticals have long been known as the “pharmacy...
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
0
In India, where urban sleep debt is rising, obesity...
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
0
When a new cancer drug shows promise, it trends...
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Subscribe
Featured Article
Pharma Case Study
Featured Article
India’s Pharma Renaissance: Private Equity at the Helm
Anup Soans
-
February 20, 2026
Read More
Featured Article
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
Anup Soans
-
February 18, 2026
Read More
Featured Article
Sleep Apnea: Apnimed Pill to Replace CPAP Machine?
Anup Soans
-
February 17, 2026
Read More
Featured Article
Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich
Anup Soans
-
February 15, 2026
Read More
Exclusive Articles
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
Anup Soans
-
February 13, 2026
Read More
Exclusive Articles
Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift
Anup Soans
-
February 12, 2026
Read More
Load more